<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9868">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05688475</url>
  </required_header>
  <id_info>
    <org_study_id>CA092-1000</org_study_id>
    <secondary_id>2022-501855-97</secondary_id>
    <secondary_id>U1111-1282-2472</secondary_id>
    <nct_id>NCT05688475</nct_id>
  </id_info>
  <brief_title>A Rollover Study of CC-122</brief_title>
  <official_title>Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating CC-122</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to provide CC-122 treatment to participants who have been&#xD;
      receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5&#xD;
      years (CC-122-ST-001 [NCT01421524], CC-122-ST-002 [NCT02509039], CC-122-DBCL-001&#xD;
      [NCT02031419], and CC-122-NHL-001 [NCT02417285]), receiving clinical benefit from the&#xD;
      treatment and to monitor the safety and tolerability of CC-122.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2023</start_date>
  <completion_date type="Anticipated">February 25, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with serious adverse events (SAEs) for participants who received at least 1 dose of CC-122</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of deaths for participants who received at least 1 dose of CC-122</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>CC-122 and Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-122</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>CC-122 and Dexamethasone</arm_group_label>
    <other_name>Avadomide</other_name>
    <other_name>BMS-986381</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>CC-122 and Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Participant who is currently receiving CC-122 on another CC-122 clinical trial that&#xD;
             has met its primary and secondary endpoints.&#xD;
&#xD;
          -  Participant who has participated in previous CC-122 protocol (including CC-122-ST-001&#xD;
             [NCT01421524], CC-122-ST-002 [NCT02509039], CC-122-DBCL-001 [NCT02031419], and&#xD;
             CC-122-NHL-001 [NCT02417285]), and is deemed by the investigator to be deriving&#xD;
             benefit from CC-122 as defined by the previous protocol.&#xD;
&#xD;
          -  Participant who is able to tolerate study therapy and has not yet experienced&#xD;
             progressive disease or any treatment discontinuation criteria of the Parent Study.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Participant is not eligible for CC-122 treatment as per the Parent Study.&#xD;
&#xD;
          -  Participants not receiving clinical benefit as assessed by the investigator. Any&#xD;
             clinical AE, laboratory abnormality, or intercurrent illness which, in the opinion of&#xD;
             the investigator, indicates that participation in the study is not in the best&#xD;
             interest of the participant.&#xD;
&#xD;
          -  Women who are breastfeeding.&#xD;
&#xD;
        Note: Other protocol-defined inclusion/exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BMS Study Connect Contact Center www.BMSStudyConnect.com</last_name>
    <phone>855-907-3286</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain the NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Medical College Of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruben Niesvizky, Site 100</last_name>
      <phone>646-258-0156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ian Flinn, Site 101</last_name>
      <phone>615-320-5090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vaishalee Kenkre, Site 102</last_name>
      <phone>608-263-1836</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fontanet Bijou, Site 300</last_name>
      <phone>+33556337801</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette Hematologie</name>
      <address>
        <city>Marseille cedex</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc Schiano De Collela, Site 301</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution - 500</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>1358550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 500</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution - 400</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 400</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>January 10, 2023</study_first_submitted>
  <study_first_submitted_qc>January 10, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>May 17, 2023</last_update_submitted>
  <last_update_submitted_qc>May 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CC-122</keyword>
  <keyword>Avadomide</keyword>
  <keyword>BMS-986381</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>Diffuse large B cell lymphoma</keyword>
  <keyword>Follicular lymphoma</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>Multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

